Kineta, Inc. KA
Set alert
At close · Sep 18
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.7801
- Prev close
- 0.5746
- Mkt cap
- 7.05M
- Vol
- 480.68K
- Avg vol
- 504.10K
- EPS
- -1.64
- P/E
- -0.35
- Div yield
- 0.00%
More statistics
- Low
- 0.56
- High
- 0.825
- Forward P/E
- -0.43
- Beta
- 0.00
- Short ratio
- 0.68
- Inst. own
- 6.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 1, 2024
- 50-d avg
- 0.649607
- 200-d avg
- 1.12
- 1y target
- 13.50
Key statistics
- Market cap
- 7.05M
- Enterprise value
- 8.55M
- Trailing P/E
- 0.00
- Forward P/E
- -0.43
- PEG ratio
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.64
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -3.17M
- Total cash
- 900.00K
- Total debt
- 710.00K
- Return on equity
- 0.00%
- Shares outstanding
- 12.26M
- Short % of float
- 0.31%
- 50-day average
- 0.649607
- 200-day average
- 1.12
Analyst view
Consensus: buy
Next earnings
Nov 1, 2024
Expected Nov 1, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 1, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.29 | — | — | — |
| Nov 3, 2023 | Sep 1, 2023 | -0.55 | — | — | — |
| Aug 11, 2023 | Jun 1, 2023 | -0.62 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 20, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| May 17, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 30, 2023 | HC Wainwright & Co. | init | — | Buy |
About Kineta, Inc.
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kinetabio.com
News
- TuHURA Biosciences Completes Acquisition of Kineta
- TuHURA Biosciences, Inc. and Kineta, Inc. Stockholders Approve Proposed Merger and All Related Proposals
- TuHURA Biosciences and Kineta Present Updated Results from Kineta's Phase I-II Study of KVA12123 and TuHURA's Mechanism of IFx-Hu2.0 Responses After Anti-PD-1 Therapy Failure in Advanced Melanoma at the American Association for Cancer Research Annual Meeting
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kineta, Inc. - KANT
- SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of TuHURA Biosciences, Inc. - HURA
- TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
- Kineta Updates KVA12123 Clinical Results from Ongoing Phase 1/2 VISTA101 Study at Society for Immunotherapy of Cancer (2024)
- Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
- Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1
- Kineta, Inc Transitioning from Nasdaq to OTC Markets
Your note
Sign in to keep a note on KA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER KEITH | Chief Financial Officer | Purchase | Sep 17, 2023 | 16,880 |
| BARTOSZEK RAYMOND JOSEPH | Director | Purchase | Dec 5, 2023 | 863,685 |
| FOOTE MARION R | Director | Conversion of Exercise of derivative security | Oct 10, 2023 | 143,204 |
| GUILLAUDEUX THIERRY | Officer | Purchase | Sep 13, 2023 | 21,696 |
| IADONATO SHAWN P | Chief Executive Officer | Purchase | Nov 28, 2023 | 683,783 |
| KENNY PAULINE | General Counsel | Purchase | Sep 19, 2023 | 18,448 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.97% | 876,000 | 2.26M | Jun 29, 2023 |
| Colony Group LLC | 1.42% | 139,201 | 359.14K | Jun 29, 2023 |
| FMR, LLC | 1.27% | 123,719 | 319.19K | Jun 29, 2023 |
| Vanguard Group Inc | 0.63% | 61,561 | 158.83K | Jun 29, 2023 |
| Artal Group S.A. | 0.32% | 31,055 | 80.12K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 0.28% | 26,916 | 69.44K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.34% | 32,976 | 85.08K | Jun 29, 2023 |
| Fidelity Growth Company Fund | 0.31% | 30,558 | 60.81K | Aug 30, 2023 |
| Vanguard Extended Market Index Fund | 0.29% | 28,255 | 72.90K | Jun 29, 2023 |
| iShares Micro Cap ETF | 0.13% | 12,978 | 25.83K | Aug 30, 2023 |
| Schwab Capital Trust-Total Stock Market Index Fund | 0.08% | 8,000 | 16.88K | Jul 30, 2023 |
| Fidelity Growth Company K6 Fund | 0.05% | 5,211 | 15.69K | May 30, 2023 |